| Identification | Back Directory | [Name]
BAY-57-1293 | [CAS]
348086-71-5 | [Synonyms]
AIC316
CS-857
Pritelivir
BAY-57-1293
Pritelivir base
PRITELIVIR;AIC316
BAY571293(Pritelivir)
Pritelivir,BAY-57-1293
PRITELIVIR; BAY-57-1293; AIC316
BAY 57-1293 - Pritelivir | AIC 316
2-METHYL-2-PROPANYL [4-(CHLOROSULFONYL)PHENYL]CARBAMATE
N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide
N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide
Benzeneacetamide, N-[5-(aminosulfonyl)-4-methyl-2-thiazolyl]-N-methyl-4-(2-pyridinyl)-
N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-(4-pyridin-2-ylphenyl)acetamide
N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide
N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide BAY57-1293 Pritelivir | [Molecular Formula]
C18H18N4O3S2 | [MDL Number]
MFCD18633192 | [MOL File]
348086-71-5.mol | [Molecular Weight]
402.49 |
| Chemical Properties | Back Directory | [Boiling point ]
639.4±65.0 °C(Predicted) | [density ]
1.396±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
insoluble in H2O; insoluble in EtOH; ≥13.9 mg/mL in DMSO | [form ]
solid | [pka]
9.31±0.60(Predicted) | [color ]
White to off-white | [InChI]
InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25) | [InChIKey]
IVZKZONQVYTCKC-UHFFFAOYSA-N | [SMILES]
C1(CC(N(C2=NC(C)=C(S(N)(=O)=O)S2)C)=O)=CC=C(C2=NC=CC=C2)C=C1 |
| Hazard Information | Back Directory | [Uses]
BAY 57-1293 is a potent inhibitor of herpes simplex virus (HSV) that target the virus helicase primase complex. | [Biological Activity]
bay 57-1293 is a potent and safe inhibitor of hsv helicase-primase with ic50 value of 12nm [1].bay 57-1293 displays anti-herpes activity through inhibiting the helicase-primase and affecting the viral dna synthesis. in the in vitro viral replication assay, bay 57-1293 shows inhibition against hsv-1 f, hsv-2 g and acyclovir-resistant hsv-1 f mutant with ic50 value of 20nm. in the plaque reduction assay and the conventional cytopathogenicity assay, bay 57-1293 shows ic50 values of 0.01-0.02μm and 0.01-0.03μm, respectively. besides that, bay 57-1293 is active at an ic50 value of 10nm–30nm against all clinical isolates of hsv-1 and hsv-2. furthermore, bay 57-1293 is active in vivo. the oral administration of bay 57-1293 shows 10-fold more potent than valacyclovir in a murine model of disseminated herpes infection. in a rat lethal challenge model, bay 57-1293 exerts profound antiviral activity without toxic effects. [1, 2] | [in vivo]
Pritelivir is the first in a class of antiviral agents that inhibit HSV replication by targeting the viral helicase-primase enzyme complex[2].
Pritelivir (0.03-45 mg/kg) significantly increases survival. Pritelivir (0.3-30 mg/kg) reduces mortality against HSV-1, E-377. Pritelivir has potent and resistance-breaking antiviral efficacy with potential for the treatment of potentially life-threatening HSV type 1 and 2 infections, including herpes simplex encephalitis[3].
Combination therapies of Pritelivir at 0.1 or 0.3 mg/kg/dose with Acyclovir (10 mg/kg/dose) are protective when compared to the vehicle treated group against HSV-2, strain MS[3]. | Animal Model: | Female BALB/c mice[3] | | Dosage: | 0.03 to 45 mg/kg | | Administration: | Administered orally, twice daily at approximately 12 h intervals, for 7 days | | Result: | Survival was significantly increased to 80-100% as compared to the vehicle treatment. Even the lowest dose of 0.3 mg/kg was effective in increasing survival to 53%. |
| [IC 50]
HSV-1: 0.02 μM (IC50); HSV-2: 0.02 μM (IC50) | [storage]
Store at -20°C | [References]
[1] kleymann g, fischer r, betz u a k, et al. new helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. nature medicine, 2002, 8(4): 392-398.
[2] betz u a k, fischer r, kleymann g, et al. potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor bay 57-1293. antimicrobial agents and chemotherapy, 2002, 46(6): 1766-1772. |
|
|